Left Ventricular Assist Device Infections by Skalweit, Marion J.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 11
Left Ventricular Assist Device Infections
Marion J. Skalweit
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.74621
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
ri  J.  l it
Additional infor ation is available at the end of the chapter
Abstract
Left ventricular assist device (LVAD) infections are important causes of morbidity and 
mortality in patients who receive these mechanical circulatory supports as a bridge to 
transplantation (BTT) or as destination therapy (DT) (for individuals who are not candi-
dates for cardiac transplant). Infections are more common among persons who received 
pulsatile flow LVADs as opposed to newer continuous flow (CF) devices. Other risk fac-
tors for infection include obesity, renal failure, depression and immunosuppression. An 
LVAD infection increases the risk of infections in persons who undergo cardiac trans-
plantation. Infections include percutaneous site, driveline, pump pocket and pump/can-
nula infections; sepsis, bacteremia, mediastinitis and endocarditis. Diagnosis is achieved 
by monitoring LVAD flow parameters and observing typical clinical and laboratory man-
ifestations of infection. Imaging such as PET-CT or SPECT-CT imaging can be helpful to 
establish a diagnosis of pump pocket infection. Echocardiography may aid in detecting 
native valve endocarditis and thrombus associated with the LVAD. The most common 
pathogens include Staphylococcus, Corynebacterium, Enterococcus, Pseudomonas and Candida 
spp. Treatment requires targeted antimicrobials plus surgical debridement of infected 
tissue and device components. In cases of pump/cannula/LVAD endocarditis, especially 
if fungal pathogens or Mycobacterium chimaera are involved, LVAD removal/reimplanta-
tion vs. transplant is necessary, combined with extended antimicrobial therapy.
Keywords: left ventricular assist device, driveline infections, pocket infection, 
endocarditis
1. Introduction
Surgical management of heart failure has revolutionized the lives of patients with symptom-
atic end stage heart disease of all causes (reviewed in [1–3]). The first left ventricular assist 
device (LVAD) was implanted in 1963 by Liotta and Crawford ([4] and references therein), 
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followed by the implantation of the first artificial heart by Cooley in 1969, as a bridge to 
transplant. The famous Jarvik 7 artificial heart was implanted in 1984 by De Vries. It was not 
until 1994 that the FDA first approved the LVAD as a bridge to transplant, and only in 2010, 
was the HeartMate II LVAD, a continuous flow (CF) device, approved as destination therapy 
([4, 5] and references therein). After January 2010, only continuous flow devices i.e. HeartMate 
II have been implanted. The HeartMate III, Heartware HVAD and the Jarvik 2000 LVADs are 
currently under study in clinical trials [6–8]. An increasing number of patients are receiving 
non-surgically deployed LVADs such as the Impella 5.0 (5 L/min flow) as they await a decision 
regarding cardiac transplantation versus destination therapy with a larger (10 L/min flow) 
standard device [9]. More and more patients who are not considered candidates for trans-
plantation are receiving destination LVADs and have significant improvement in their NYHA 
functional class and quality of life despite the numerous potential complications that these 
patients often face [1, 10, 11]. As devices evolve, becoming ever smaller, more compact and 
potentially entirely contained within the patient, it is anticipated that many of the complica-
tions, particularly infectious complications, will diminish in frequency. However, with the cur-
rent state-of-the-art, infectious complications including drive line infections, pocket infections, 
bacteremia and the most dreaded infectious complication, endocarditis and associated mycotic 
aneurysms, remain important causes of morbidity and mortality in LVAD recipients, both des-
tination therapy (DT) and as a bridge-to-transplant (BTT). In this review, we will not consider 
complications of devices used in so-called “bridge to decision” therapy such as the Impella 5.0.
The continuous axial flow HeartMate II is now the most common LVAD in use in the US; 
between 2006 and 2016 a total of 17,008 CF LVADS have been implanted with 81% 1 year 
survival [12]. LVADs including HeartMate II and other devices have been reviewed in [1, 3, 4, 
13–17]. Newer centrifugal flow devices, HeartMate III and HeartWare HVAD that are smaller 
and reportedly less prone to thrombosis and device failure are in clinical trials in the US [7, 8, 
18] but have been utilized successfully in other parts of the world [19].
This review will focus on several aspects of LVAD infections including the rare complication 
of endocarditis, and will identify gaps in knowledge regarding diagnosis of LVAD infections, 
treatment and prevention of these infections. Differences in rates of infection in bridge vs. 
destination therapy will be discussed but the focus of review will be on destination therapy 
as that is where we see the most infectious complications. The epidemiology and microbiol-
ogy of LVAD infections will also be addressed including risk factors and the impact of device 
related complications on post-transplant infectious complications. Mycobacterium chimaera 
LVAD infections will also be discussed.
2. Epidemiology and risk factors for LVAD infections
Several studies have looked at various aspects of LVAD candidates in terms of their risk 
of developing complications including infections. A significant reduction in infections has 
already been noted in a randomized trial comparing older pulsatile flow LVADs to current 
continuous flow (CF) LVADs [5]. The improvement in infection rates was felt to be due to the 
smaller size of the device and the driveline caliber [20]. An observational study of LVAD type 
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(pulsatile versus CF) spanning 2000–2009 in a single institution concluded that differences 
in infectious complications in that cohort were more related to when the device had been 
implanted, with more recent implantations showing fewer infections [21]. Subsequent inno-
vations (axial to centrifugal flow) have not resulted in a reduction in infectious complica-
tions [7, 8] with an actual increase in sepsis with the Heartware HVAD device compared to 
HeartMate II control [7]. Studies have looked at factors including age [22], gender [23], body 
habitus including both small patients [24] and obesity [25], trauma [26], duration of LVAD 
support [27] as well as presence of comorbid conditions such as diabetes [28–30], depres-
sion and chronic kidney disease (CKD) [31], alcoholism and immunosuppression [29], and 
malnutrition ([32, 33] and references therein). In a Japanese multicenter trial looking at 300 
patients receiving HeartMate II between April 2013 and December 2016, patients older than 
60 had similar overall survival and risk of driveline and pocket infections [22]. An older 
study found that age and the presence of diabetes were associated with increased risk of 
LVAD endocarditis [34] with a median age of 59 among patients with endocarditis compared 
with a median age of 53 in those without (p = 0.02). Women receiving LVADs were often 
sicker (Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS) 
cohorts 1 or 2) and had significantly higher bleeding complications, arrhythmias and right 
heart failure, but not infectious complications [23]. Driveline infections were slightly more 
common in smaller (body surface area (BSA) < 1.5 m2) patients (13 vs. 12 patients, p = 0.003) 
but mediastinal infections occurred in 2 patient with BSA > 1.5 m2 with no cases among 
smaller patients [24]. Clerkin et al. examined data from a BTT cohort of 3856 patients 
between 2004 and 2014, and found that patients with a body mass index (BMI) >35 kg/m2 
had a trend towards increased infection risk (hazard ratio 1.59, 95% confidence interval 
0.99–1.94, p = 0.058) [25]. Diabetes mellitus as a risk factor for infection was studied among 
341 individuals who underwent LVAD implantation at Mayo Clinic between 2007 and 2016 
[28]. Thirty-eight percent of the LVAD recipients had diabetes, and those patients also had 
significantly more ischemic cardiomyopathy as a cause for LVAD implantation, more were 
receiving LVADS as destination therapy and these patients also had higher BMI than those 
without diabetes. Looking at a composite endpoint of stroke, pump thrombosis and infec-
tions, patients with diabetes were 2.1 times more likely to have a poor outcome. There was a 
1.73 fold increased risk of all cause mortality among diabetic patients as well. Interestingly, 
pre-operative hemoglobin A1C (HgbA1c) levels were not related to adverse outcomes, and 
LVAD recipients experienced lower HgbA1cC levels and lower diabetes medication require-
ments post-implantation. A large prospective multicenter trial of 86 HeartMate II recipients 
identified depression and CKD as independent risk factors for infection [31], with adjusted 
hazard ratios of 2.8 (p = 0.007) and 1.7 (p = 0.023) respectively. A multicenter trial in France 
looked at 159 patients who received LVADs between 2007 and 2012 and found that 22.6% 
of the patients had at least one infectious complication [29]. LVAD infections in this cohort 
were associated with alcoholism in 33%, diabetes in 11% and other immunosuppression in 
11%. Of note, a small case series of 4 HIV patients implanted with LVADs did not show an 
increased risk in infection and one of the patients was successfully transplanted [35]. The 
implantation of an LVAD itself seems to result in reduced cell mediated immunity with 
decreased interleukin-2 (IL-2) and tumor necrosis factor (TNF) production, and increased 
IL-10 by T-lymphocytes. Greater numbers of suppressive regulatory T-lymphocytes (T
regs
) 
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are found in these patients for an average of 6 months post-implantation ([36], also reviewed 
in [33]). LVAD induced immune deficits appear to resolve in CF devices as compared to 
older pulsatile devices ([33] and references therein).
2.1. Impact on post-transplant infections
Additional studies have looked at outcomes in transplant patients who developed LVAD 
infections either as BTT or DT (where the infection was treated in part by removal of the 
DT device, with subsequent receipt of an organ) [20, 30, 34, 37, 38]. In US studies, pre-
transplant LVAD infections appear to influence outcomes in cardiac transplant patients, 
with more infectious complications in those with prior LVAD infectious complications. 
Other risk factors in multivariate analysis included age, ICU length of stay and use of 
an anti-thymocyte agent [38]. A sub-study of the Swiss Transplant Cohort Study found 
that pre-transplant LVAD infections did not have an impact on post-transplant outcomes 
with slightly lower rates of infection and slightly higher survival rates among LVAD BTT 
patients [37]. Enterococcal infections including with VRE and Staphylococcal infections 
were most common among LVAD associated post transplant infections [30, 34]. The pres-
ence of infections with molds such as Aspergillus spp. are felt to be a strong relative contra-
indication for transplantation [6].
3. Microbiology of LVAD infections
The microbiology of LVAD infections has been extensively reviewed [20, 26, 27, 29–31, 33, 
34, 37, 39–43]. In the main, LVAD infectious etiology is related to the particular clinical syn-
drome e.g. driveline infection vs. pocket infection vs. endocarditis. The International Society 
for Heart and Lung Transplantation classifies infections as “VAD related” or “VAD specific” 
to refer to bacteremia, endocarditis and mediastinitis versus driveline, pocket and pump/can-
nula infections [13]. INTERMACS lists non-device related infections, device related infections 
(internal pump infections; percutaneous site infections and pocket infections (listed together)) 
and sepsis [12].
3.1. Bacteremia and sepsis
Bacteremia and sepsis are seen most frequently in the peri-operative period and often these 
infectious disease syndromes are associated with non-VAD infections such as central line 
associated blood stream infections (CLABSIs), ventilator and hospital associated pneumonia, 
urinary tract infections, Clostridium difficile associate diarrhea and colitis. The microbiology of 
these peri-operative non-VAD infections has been reviewed in the references above and will 
not be covered again in this chapter.
LVAD related bacteremias can also occur with associated sepsis, and may be related to device 
infections (pump pocket, pump/cannula), infective endocarditis and mediastinitis. The organisms 
detected in bacteremic patients (e.g. Staphylococci, Enterobacteriaceae, Pseudomonas aeruginosa, 
Enterococci, Candida spp.) are indicative of at least some of the possible device related organisms 
causing infection [20, 31, 34, 37, 40, 43, 44].
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3.2. Driveline infections
Driveline infections are most common, and skin flora from patient’s skin are the predominant 
pathogens detected (reviewed in [40]). Often, trauma of the driveline tunnel, due to rough 
manipulation of the driveline, and lack of skin fixation that reduces tension on the driveline, 
leads to infections. The microbiology includes Staphylococcus aureus, both methicillin suscep-
tible (MSSA) and resistant (MRSA), coagulase negative Staphylococci (CNS) (S. epidermidis), 
Corynebacterium spp. [21, 26, 27, 33, 34, 45, 46], viridans streptococci [31], Enterococcus faecalis 
[31, 34], E. faecium including vancomycin resistant strains “VRE” [30], Gram negative enteric 
bacilli such as Enterobacteriaceae (Enterobacter cloacae and E. aerogenese [31] Escherichia coli, 
Klebsiella spp. [34], Proteus mirabilis [31], Serratia marcescens [21]), Pseudomonas aeruginosa [20, 
26, 31] and Stenotrophomonas maltophilia [31]. There have been rare instances of fungal drive-
line infections with Candida spp. such as C. albicans, glabrata [20, 31, 34]. There have been recent 
series of reports of infections with Mycobacterium chimaera, related to open chest surgery and 
cooling units employed for cooling cardioplegia solution [47]. In rare cases, patients devel-
oped endocarditis in the setting of recent valvular surgery. To date, one case of a complicated 
LVAD driveline infection with abdominal wall abscess by M. chimaera has been reported [48].
Biofilm formation by many different organisms contributes to persistence of infections due to 
the poor efficacy of antibiotics against organisms within biofilms, even when drug resistance 
is not present [33, 40, 43, 49].
3.3. Pocket infections
Pocket infections can occur at the time of implantation, during trauma to the driveline and 
pocket from driveline manipulation or bleeding into the pocket from coagulopathies [20]. 
The microbiology of pocket infections is thus very similar to driveline infections, with skin 
flora such as Staphylococci and Corynebacteria predominating, as well as Enterobacteriaceae, 
Enterococci, Pseudomonas and Candida spp. [20, 26, 31, 40]. We are in the process of reporting 
on a patient with a HeartMate II LVAD for DT who cracked his driveline and had extensive 
hematoma formation in the pump pocket with subsequent persistent infection and bactere-
mia with Enterobacter cloacae (Skalweit, in preparation). Computed tomography images of this 
patient are shown in Figure 1, with hematoma, phlegmon and small air bubbles evident in 
the pump pocket (a) before debridement. Figure 1b is after debridement. Figure 2a–c shows 
the pump pocket wounds after debridement, with placement of a vacuum wound device and 
after closure of the defect. One case of a pocket infection with M. chimaera has been reported in 
a patient who developed a fluid collection contiguous with the pump pocket [48]. The patient 
underwent extensive debridement and omental flap coverage of the device. Operative speci-
mens were routinely cultured and he was empirically treated with broad spectrum antibiotics 
but did not respond to therapy. Subsequent mycobacterial cultures revealed the pathogen 
and he was maintained on lifelong M. chimaera therapy.
3.4. Mediastinitis
As a direct extension of pocket infections or as a result of sternal wound infections, LVAD 
associated mediastinitis is rarely observed [34, 43, 48]. S. aureus (MRSA), CNS, and vancomycin 
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susceptible E. faecalis were the reported pathogens in five patients with LVAD mediastinitis 
[34]. A single case of fungal mediastinitis presenting with LVAD outflow obstruction caused 
by growth of Syncephalastrum racemosum has been reported [50]. The concern with mediastinal 
infection is always one of extension to involve the great vessels, the pericardium and bone, 
requiring potential additional source control and extended antibiotic therapy.
3.5. Infective endocarditis and pump/cannula infections
Endovascular infections can occur on native valves, prosthetic valves as well as in association 
with the LVAD pump body and cannula and are associated with high mortality [26]. Early case 
reports with older generation pulsatile flow devices described LVAD valve replacement on a 
Novacor N100 LVAD [51]; pathology revealed Gram positive cocci. A series of fungal LVAD 
Figure 1. (a and b) Computed tomography (CT) images of pump pocket infection before (a) and after (b) surgical 
debridement. Solid arrows show the location of a complex hematoma, phlegmon and air bubbles. Operative cultures 
grew a susceptible Enterobacter cloacae.
Figure 2. (a–c) Wound care in Enterobacter cloacae pump pocket infection, post debridement (a), with wound vacuum 
device placement (b) and after healing (c). Heavy and dotted arrows indicate the pump pocket wounds, dashed arrow 
is the driveline.
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infections revealed that 3% met criteria for LVAD endocarditis (cultures of blood and explanted 
LVADs positive for fungal pathogens) [50]. Candida albicans, C. parapsilosis and S. racemosum 
were isolated in 3, 1 and 1 case respectively. More recently in the continuous flow era, LVAD 
associated endocarditis has been defined as “clinical evidence of pump and/or cannula infec-
tion along with the presence of vegetations on echocardiography or a vascular phenomenon as 
defined by modified Duke’s criteria” ([26] and reviewed in [42]). Staphylococcus aureus (MRSA, 
MSSA) predominates, as well as CNS (MRSE, MSSE) and Pseudomonas aeruginosa (reviewed 
in [42]). Cases of linezolid resistant Streptococcus sanguinis [52] and Listeria monocytogenes [53] 
with associated leukocytoclastic vasculitis have also been reported.
3.6. Cerebrovascular microbleeds/stroke/mycotic aneurysm
Other complications related to LVAD infections can include hemorrhagic stroke and mycotic 
aneurysm. Patients with heart failure are already at risk of thrombosis, and increased infec-
tious complications and coagulopathy associated with LVADs increases the risk of device 
thrombosis and stroke (reviewed in [54]). Aggarwal et al. [55] studied the relationship 
between bacteremia and stroke in LVAD patients in a retrospective chart review study. They 
studied 80 patients who had undergone LVAD placement in their institution, of whom 30 
developed blood stream infections. Among those 30, 13 developed hemorrhagic strokes (43%) 
compared to 5/ 50 (10%) in LVAD recipients without bacteremia. In their report, the majority 
of BSI were caused by Staphylococci (CNS, MRSA). Yoshioka et al. found a similar association 
with hemorrhagic stroke in patients with either bacteremia or pump pocket infection [56, 57]. 
Organisms isolated among the nine patients in their study with hemorrhagic stroke included 
methicillin susceptible S. epidermidis (MSSE), MSSA, Corynebacterium spp., MRSA, CNS, E. 
faecalis, Bacillus sp. and Campylobacter sp. A rare complication in an LVAD recipient is mycotic 
aneurysm related to prior recurrent Klebsiella rhinoscleromatis bacteremia and subarachnoid 
hemorrhage [58].
3.7. Drug resistance
Prior treatment with antibiotics and extended therapy with narrow spectrum antibiotics did 
not appear to increase risk for LVAD infections with multidrug resistant organisms (MDRO) 
[59]; MDRO infections were related to indication (DTT > BT), obesity and driveline technique 
(“velour exposed” versus buried). However, a recent case series reported that high level dap-
tomycin resistance in Corynebacterium striatum LVAD infections was selected for by using dap-
tomycin as treatment [60].
4. Diagnosis of LVAD infections
LVAD infections can manifest in many ways from indolent infections in patients that are mini-
mally symptomatic to septic patients requiring intensive care. Most sources [13, 27, 39, 40, 
43, 61, 62] agree on general investigations that should occur in order to diagnose an LVAD 
related or device specific infection. If LVAD infection is suspected, driveline and three sets 
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of blood bacterial cultures before antibiotics are administered should be obtained, in addi-
tion to routine laboratories: complete blood count (CBC); complete chemistries including 
LDH; coagulation studies (fibrinogen, platelets, d-Dimer, Factor VIII, INR, PTT); erythro-
cyte sedimentation rate, C-reactive protein). Procalcitonin is elevated in the initial post-
operative period and does not appear to be a useful marker of infectious complications 
[63]. Imaging of the driveline and pump pocket using ultrasound has been suggested 
by some groups to assess for fluid in the pump pocket or tracking along the driveline. 
Computed tomography (CT) scanning is of limited utility due to the reflective properties of 
the pump body. However positron emission tomography (PET-CT) [64]; or gallium single 
photon emission computed tomography (SPECT-CT) [64–66], reviewed in [40]) have been 
used to diagnose infection of LVAD components as well as to assess for metastatic sites 
of infection often found with prolonged bacteremia with pathogens such as S. aureus and 
P. aeruginosa (reviewed in [40, 67, 68]). Erba et al. [69] showed that 99mTc-hexamethypro-
pylene amine oxime labeled autologous white blood cell (99mTc-HMPAO-WBC) SPECT-CT 
had 94% sensitivity at detecting cardiac implantable electronic device infections, with 95% 
negative predictive value in patients with other sources of infection. Inflammation from 
driveline trauma may result in a positive PET-CT image, even in the absence of infection. 
Transesophageal echocardiography is utilized in the setting of positive blood cultures to 
look for vegetations on native valves or on device components [26, 44, 62]. However, it has 
been previously acknowledged that echocardiography may be of limited use in evaluating 
for vegetations, due to reflections off of the device’s reflective metal surfaces [50]. The role 
of echocardiography [70] and the application of newer techniques such as real time three 
dimensional (3D) echo has been reviewed [71] and discusses utility in evaluating native 
valves and presence of thrombus.
LVAD parameters such as flow rates may also be an indication of infectious complications 
[61]. Elevations of B-type natriuretic peptide (BNP) were also found to be a marker of serious 
adverse events in LVAD patients, including severe infections such as sepsis, mediastinitis 
and pump pocket infections [72]. Thrombosis, alteration in coagulation parameters, stroke, 
acute renal failure may also be early indicators of infection as well as more routine signs 
such as fever, leukocytosis and localizing signs and symptoms.
Additional microbiologic techniques such as fluorescent in situ hybridization (FISH) and 
polymerase chain reaction (PCR) have been used to identify additional pathogens in biofilm 
obtained from explanted LVADs and may provide supplemental information on which to 
base antimicrobial selection [73].
5. Outcomes in LVAD infections
Clinical outcomes for LVAD implantation have been extensively reviewed (see for example 
[10, 61, 74, 75]) including for infection. It is estimated that 15% of LVAD recipients die due 
to infectious complications, with the majority of deaths occurring within the first 30 days of 
receipt [76]. More than half of the data available for review is for patients receiving CF devices 
for BTT indications. Overall rates of infection for CF devices in trials and registries with more 
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than 100 patients were follows: local site infections 20–49%; driveline infections 12–22%; 
pocket infections 2–5%; sepsis 3–36%; other types of infections 26–35% [10]. It is estimated 
from the INTERMACS registry data [12] that there are 8 infectious complications per 100 
patient-months in CF LVAD recipients. The European Registry for Patients with Mechanical 
Circulatory Support (EUROMACS), a European registry of LVAD recipients includes data 
from 52 hospitals from 2681 patients with 2947 implants since 2014 [77]. Overall serious 
infection rates were 6.18 per 100 patient months within the first 3 months of implantation. 
Three year survival was only 44% in patients with CF devices, and 20% of the deaths were 
attributable to infections. In a retrospective study of 88 CF LVAD implantations (22% DT) 
between 2006 and 2014 at the Toronto General Hospital, 129 readmissions occurred, of which 
17% were related to infections [78]. Despite this readmission rate (63% with at least one read-
mission), outcomes were excellent with only 6 deaths. Other analysis of the INTERMACS 
registry revealed that 19% of LVAD recipients developed a percutaneous site infection within 
12 months of receiving a CF LVAD [79]. Ten percent of patients with these infections died, with 
sepsis being the most common cause of death (26%) [79]. In general, DT is associated with 
greater infection risk, and recurrence of infection, especially driveline infections. The major-
ity of these infections are driveline infections and outcomes are generally good (reviewed in 
[80, 81]). Fortunately with infection control techniques, rates of driveline infections appear to 
be decreasing [82]. Pocket infections are less common but can confer greater risks of morbid-
ity including hemorrhagic stroke [56, 57]. In a large prospective study of infections after car-
diac operations, Perrault et al. found that LVAD and transplant patients experienced 5.8 times 
higher rates of mediastinal infections (95% CI 2.36–14.33) with five times higher readmission 
and mortality rates [83]. Nearly all cases of LVAD endocarditis will require explanation and 
replacement of the device as well as prolonged antimicrobial therapy, and the risks associated 
with these [42]. Outcomes are improving overall however. Among 156 patients who survived 
more than 4 years in one center, the mean survival was 7 years with ~1 readmission per year 
[84]. In terms of overall quality of life, 92% of these patients were NYHA Class I or II. The most 
common reason for readmission was infection (10%).
6. Treatment and prevention of LVAD infections
Management of LVAD infections is related to the specific LVAD infectious clinical syndrome 
[13, 26, 27, 30, 31, 42, 43]. Typically, combined medical-surgical treatment is needed, with 
infectious disease consultation to determine the best selection of empiric and microbiologi-
cally driven antimicrobials. Site infections and driveline infections are typically managed with 
local wound care and a combination of intravenous then oral antibiotics if possible as dictated 
by the organism isolated from the infected site. Percutaneous site infections have even been 
treated with topical agents such as crystal violet [85]. Sometimes the tunnel must be excised, 
and a new tunnel created with the application of a vacuum wound device to close the defect. 
Certain infections have been prevented by reducing exposed driveline material (velour) by 
keeping it entirely in the subcutaneous tunnel [82]. Preventing trauma to the driveline by use 
of anchoring devices [86], and use of sterile technique when changing the driveline dressing 
are key in preventing driveline infections. Standardized strategies for driveline dressings, and 
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in overall LVAD infection control within hospitals are also helpful in preventing infections 
[86–88]. Pocket infections must typically be managed with surgical debridement in the oper-
ating room with techniques such as omental wrapping of the pump housing to cover exposed 
metal and to close surgical defects [89, 90]. In rare instances, extrapolating from the orthopedic 
surgery literature, antibiotic impregnated beads have been placed in the pocket (reviewed in 
[91, 92]) although this has not been studied in a rigorous manner. Arguably, tissue levels of par-
enteral antibiotics are sufficient to treat residual infection once source control has been achieved. 
Placement of an additional foreign body in the pocket may not be advised, especially since 
the antibiotic concentrations from the beads will eventually wane, requiring subsequent bead 
exchange or removal. Repeated exposure to sub-inhibitory concentrations of antibiotic can lead 
to selection of antibiotic resistant organisms. Indolent pathogens such as M. chimaera or in the 
case of fungal infections may necessitate exchange of the pump and other components that are 
involved. LVAD endocarditis requires explanation and extended antimicrobial therapy, poten-
tially with lifelong suppression if re-implanted or if cardiac transplantation occurs [42, 48, 50].
Optimal peri-implant antibiotic prophylaxis has not been established in a rigorous trial. However, 
“best evidence” was provided in a review by Acharya et al. [93] and consists of antibiotic cover-
age for Staphylococci, Enterococci, Pseudomonas and Candida spp. They concluded that use of an 
extended spectrum beta-lactam plus vancomycin in areas where rates of methicillin resistant 
S. aureus are high, a fluoroquinolone, fluconazole and mupirocin ointment (nasal application) 
in the “peri/post-operative” period (~3 days) was recommended. Prophylactic antibiotics are 
not recommended to prevent driveline infection after the immediate post-operative period [94].
7. Future directions
The development of biventricular or LVAD devices with transcutaneous energy sources (“TETs”) 
will eliminate driveline infections [95]. However, this remains the “holy grail” for developers of 
mechanical circulatory support devices [96, 97]. Magnetically levitated pumps help reduce the 
rates of reoperation (and attendant complications like infection) [7]. Changes in size and materi-
als involved in these devices can also reduce risk of thrombosis and enable easier explanation 
and reimplantation should complications arise [98]. Minimally invasive procedures such as off-
pump implantation and alternative implant sites may also lead to reduced infection risk [99].
8. Conclusions
Left ventricular assist device (LVAD) infections are important causes of morbidity and mortal-
ity in patients who receive these mechanical circulatory supports as a bridge to transplanta-
tion (BTT) or as destination therapy (DT) (for individuals who are not candidates for cardiac 
transplant). Infections are more common among persons who received pulsatile flow LVADs 
as opposed to newer continuous flow (CF) devices. Other risk factors for infection include 
obesity, renal failure, depression and immunosuppression although HIV positive LVAD 
recipients have not had increased rates of infection in the limited number of recipients to 
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date. An LVAD infection increases the risk of infections in persons who undergo cardiac trans-
plantation. Infections include percutaneous site, driveline, pump pocket and pump/cannula 
infections; sepsis, bacteremia, mediastinitis and endocarditis. Diagnosis is achieved by moni-
toring LVAD flow parameters and observing typical clinical and laboratory manifestations 
of infection (fever, local induration, erythema, abdominal pain, high flow LAVD parameters, 
leukocytosis, elevated inflammatory markers such as ESR, CRP; markers of coagulopathy). 
Elevated BNP may herald severe infection such as sepsis and pump pocket infection. PCR 
and FISH microbiologic techniques increase diagnostic yield of specific pathogens in biofilm 
on drivelines and other device components. Imaging such as PET-CT or SPECT-CT imaging 
can be helpful to establish a diagnosis of pump pocket infection. Echocardiography may aid 
in detecting native valve endocarditis and thrombus associated with the LVAD. The most 
common pathogens include Staphylococcus, Corynebacterium, Enterococcus, Pseudomonas and 
Candida spp. Treatment requires targeted antimicrobials plus surgical debridement of infected 
tissue and device components. In cases of pump/cannula/LVAD endocarditis, especially if 
fungal pathogens or Mycobacterium chimaera are involved, LVAD removal/re-implantation vs. 
transplant is necessary, combined with extended antimicrobial therapy. The “holy grail” of 
future mechanical circulatory support is a fully implantable device that relies on transcutane-
ous energy supplies. Devices of the future would be less prone to infectious complications 
potentially but would not entirely eliminate infectious complications. Smaller devices with 
magnetically levitated pumps, minimally invasive techniques and uniform infection control 
practices are the state-of the art in preventing infectious complications of LVADs today.
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